DAMORA THERAPEUTICS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
DAMORA THERAPEUTICS, INC. (DMRA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$22.00K, a 104.32% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$48.00K, a 123.65% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$21.00K.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $14.00K, a 97.01% decline year-over-year.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $705.00K.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$283.00K, a 145.35% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $624.00K, a 721.05% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $76.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.00K 10-Q · filed 2026-08-10 | -$70.00K 10-Q · filed 2026-08-10 | -$91.00K derived: sum of 3 quarters · filed 2026-08-10 | -$77.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$48.00K 10-Q · filed 2026-05-12 | -$69.00K derived: sum of 2 quarters · filed 2026-05-12 | -$55.00K derived: sum of 3 quarters · filed 2026-05-12 | $454.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$7.00K derived: sum of 2 quarters · filed 2026-03-19 | $502.00K derived: sum of 3 quarters · filed 2026-08-10 | $705.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $14.00K 10-Q · filed 2025-11-06 | $523.00K derived: sum of 2 quarters · filed 2026-08-10 | $726.00K 10-Q · filed 2025-11-06 | $158.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $509.00K 10-Q · filed 2026-08-10 | $712.00K 10-Q · filed 2026-08-10 | $144.00K derived: sum of 3 quarters · filed 2026-08-10 | $612.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $203.00K 10-Q · filed 2026-05-12 | -$365.00K derived: sum of 2 quarters · filed 2026-05-12 | $103.00K derived: sum of 3 quarters · filed 2026-05-12 | -$26.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$100.00K derived: sum of 2 quarters · filed 2026-03-19 | -$229.00K derived: sum of 3 quarters · filed 2026-03-19 | -$283.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $468.00K 10-Q · filed 2025-11-06 | $339.00K derived: sum of 2 quarters · filed 2025-11-06 | $285.00K 10-Q · filed 2025-11-06 | $619.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$129.00K 10-Q · filed 2025-08-05 | -$183.00K 10-Q · filed 2025-08-05 | $151.00K derived: sum of 3 quarters · filed 2025-08-05 | $334.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$54.00K 10-Q · filed 2025-05-08 | $280.00K derived: sum of 2 quarters · filed 2025-05-08 | $463.00K derived: sum of 3 quarters · filed 2025-05-08 | $453.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $517.00K derived: sum of 2 quarters · filed 2025-03-19 | $507.00K derived: sum of 3 quarters · filed 2025-03-19 | $624.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $183.00K 10-Q · filed 2024-11-01 | $173.00K derived: sum of 2 quarters · filed 2024-11-01 | $290.00K 10-Q · filed 2024-11-01 | $1.97M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$10.00K 10-Q · filed 2024-08-12 | $107.00K 10-Q · filed 2024-08-12 | $1.79M derived: sum of 3 quarters · filed 2024-08-12 | $1.36M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $117.00K 10-Q · filed 2024-04-29 | $1.80M derived: sum of 2 quarters · filed 2024-04-29 | $1.37M derived: sum of 3 quarters · filed 2024-04-29 | $568.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $1.25M derived: sum of 2 quarters · filed 2024-03-08 | $451.00K derived: sum of 3 quarters · filed 2024-03-08 | $76.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$426.00K 10-Q · filed 2023-11-06 | -$1.23M derived: sum of 2 quarters · filed 2023-11-06 | -$1.60M 10-Q · filed 2023-11-06 | -$1.84M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$804.00K 10-Q · filed 2023-07-31 | -$1.18M 10-Q · filed 2023-07-31 | -$1.41M derived: sum of 3 quarters · filed 2023-07-31 | -$1.75M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | -$375.00K 10-Q · filed 2023-04-28 | -$606.00K derived: sum of 2 quarters · filed 2023-04-28 | -$941.00K derived: sum of 3 quarters · filed 2023-04-28 | -$765.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$566.00K derived: sum of 2 quarters · filed 2023-03-09 | -$390.00K derived: sum of 3 quarters · filed 2023-03-09 | -$994.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$335.00K 10-Q · filed 2022-11-08 | -$159.00K derived: sum of 2 quarters · filed 2022-11-08 | -$763.00K 10-Q · filed 2022-11-08 | $226.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $176.00K 10-Q · filed 2022-07-29 | -$428.00K 10-Q · filed 2022-07-29 | $561.00K derived: sum of 3 quarters · filed 2022-07-29 | $2.89M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | -$604.00K 10-Q · filed 2022-04-29 | $385.00K derived: sum of 2 quarters · filed 2022-04-29 | $2.72M derived: sum of 3 quarters · filed 2022-04-29 | $2.73M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $3.32M derived: sum of 2 quarters · filed 2022-02-17 | $3.33M derived: sum of 3 quarters · filed 2022-02-17 | $3.13M 10-K · filed 2022-02-17 |
| 2020-09-30 | $2.33M 10-Q · filed 2021-11-04 | $2.35M derived: sum of 2 quarters · filed 2021-11-04 | $2.14M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $15.00K 10-Q · filed 2021-08-05 | -$195.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |